Faber J P, Poller W, Weidinger S, Kirchgesser M, Schwaab R, Bidlingmaier F, Olek K
Institut für Klinische Biochemie der Universität Bonn, Germany.
Am J Hum Genet. 1994 Dec;55(6):1113-21.
We have investigated the molecular basis of 15 new alpha 1-antitrypsin (alpha 1AT) variants. Phenotyping by isoelectric focusing (IEF) was used as a screening method to detect alpha 1AT variants at the protein level. Genotyping was then performed by sequence analysis of all coding exons, exon-intron junctions, and the hepatocyte-specific promoter region including exon Ic. Three of these rare variants are alleles of clinical relevance, associated with undetectable or very low serum levels of alpha 1AT:the PIQ0saarbruecken allele generated by a 1-bp C-nucleotide insertion within a stretch of seven cytosines spanning residues 360-362, resulting in a 3' frameshift and the acquisition of a stop codon at residue 376; a point mutation in the PIQ0lisbon allele, resulting in a single amino acid substitution Thr68(ACC)-->Ile(ATC); and an in-frame trinucleotide deletion delta Phe51 (TTC) in the highly deficient PI*Mpalermo allele. The remaining 12 alleles are associated with normal alpha 1AT serum levels and are characterized by point mutations causing single amino acid substitutions in all but one case. This exception is a silent mutation, which does not affect the amino acid sequence. The limitation of IEF compared with DNA sequence analysis, for identification of new variants, their generation by mutagenesis, and the clinical relevance of the three deficiency alleles are discussed.
我们研究了15种新的α1 -抗胰蛋白酶(α1AT)变体的分子基础。通过等电聚焦(IEF)进行表型分析,作为一种筛选方法,用于在蛋白质水平检测α1AT变体。然后通过对所有编码外显子、外显子 - 内含子连接区以及包括外显子Ic的肝细胞特异性启动子区域进行序列分析来进行基因分型。其中三种罕见变体是具有临床相关性的等位基因,与无法检测到或血清中α1AT水平极低有关:PIQ0saarbruecken等位基因是由在跨越360 - 362位残基的七个胞嘧啶片段内插入1个碱基对的C核苷酸产生的,导致3'移码并在376位残基处获得一个终止密码子;PIQ0lisbon等位基因中的一个点突变,导致单个氨基酸取代Thr68(ACC)→Ile(ATC);以及高度缺陷的PI*Mpalermo等位基因中的一个框内三核苷酸缺失ΔPhe51(TTC)。其余12个等位基因与正常的α1AT血清水平相关,除了一个案例外,其特征均为点突变导致单个氨基酸取代。这个例外是一个沉默突变,不影响氨基酸序列。讨论了与DNA序列分析相比,IEF在鉴定新变体、通过诱变产生新变体以及三种缺陷等位基因的临床相关性方面的局限性。